Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Irish biotech Elan (NYSE: ELN) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Elan's business and see what CAPS investors are saying about the stock right now.
Elan facts
Headquarters (Founded)
Dublin, Ireland (1969)
Market Cap
$3.1 billion
Industry
Pharmaceuticals
Trailing-12-Month Revenue
$1.08 billion
Management
CEO Kelly Martin (since 2003)
CFO Shane Cooke (since 2001)
Return on Capital (Average, Past 5 Years)
(4.6%)
Cash / Debt
$1.1 billion / $915 million
Competitors
Pfizer (NYSE: PFE)
Bristol-Myers Squibb (NYSE: BMY) Continued...
Brian D. Pacampara is an investment expert and analyst for the Motley Fool.
Be the first to read Brian D. Pacampara's column. Sign up today and receive Townhall.com delivered each morning to your inbox.